Psilocybin and Glutamate: Beyond the Serotonin Story

Psilocybin Non-Serotonin Mechanisms

7T MRI directly measured glutamate during ego dissolution

Mason and colleagues placed participants in a 7-Tesla MRI scanner during a psilocybin session and measured brain glutamate levels in real time. The resulting data showed region-specific glutamate changes that predicted the character of the ego dissolution experience.

Mason et al., Neuropsychopharmacology, 2020

mPFC ↑

prefrontal glutamate increase correlated with negative ego dissolution (Mason 2020)

Hippocampus ↓

decreased hippocampal glutamate correlated with positive ego dissolution (Mason 2020)

mGluR2

psilocybin reversed alcohol-induced glutamate receptor downregulation in animal model (Meinhardt 2021)

Mason et al., Neuropsychopharmacology, 2020

View as image ↗

Most explanations of how psilocybin works start and end with serotonin. Psilocybin is metabolized to psilocin, which binds the 5-HT2A serotonin receptor. The receptor triggers downstream cell signaling. End of story, in most accounts.

The actual mechanism is more layered. When psilocin activates 5-HT2A receptors on the pyramidal cells of the cortex, those cells release glutamate — the brain's primary excitatory neurotransmitter. That glutamate release then drives a cascade of effects across the prefrontal cortex, hippocampus, and subcortical regions, engaging receptor systems and circuits that are not serotonergic at all. The serotonin receptor is the initiating step. Much of what happens afterward involves glutamate.

This was speculation based on preclinical models until 2020, when Mason and colleagues published direct human evidence. They placed participants in a 7-Tesla MRI scanner, used magnetic resonance spectroscopy to measure glutamate concentrations in specific brain regions, and administered psilocybin inside the scanner. The glutamate changes they measured predicted, with regional specificity, what kind of ego dissolution the person experienced.^[1]

This article covers what the research shows about psilocybin's glutamatergic mechanisms, why they matter for understanding both the experience and the therapy, and how they connect to the broader multi-system picture that has emerged from pharmacological research.

For background on the serotonergic foundation, see How 5-HT2A Agonism Creates the Psychedelic Experience, and for the full neuroscience framework, see Psilocybin and the Default Mode Network: How It Quiets the Ego.

The Most Direct Evidence: A 7T MRI Scanner Measuring Glutamate During Psilocybin

Magnetic resonance spectroscopy can measure the concentration of specific molecules in defined brain regions. Most MRI scanners in clinical settings operate at 1.5 to 3 Tesla. At 7 Tesla, the signal-to-noise ratio improves substantially — enough to detect changes in metabolites like glutamate with the spatial resolution needed to compare regions.

Mason and colleagues at Imperial College London used this approach with psilocybin in 2020.^[1] Participants received a dose of 0.17 mg/kg psilocybin — a moderate dose that reliably produces ego dissolution in most people — and lay in the 7T scanner while their brain chemistry was measured. The researchers focused on the medial prefrontal cortex, the region most consistently implicated in self-referential thinking and in the default mode network, and the hippocampus, a central memory and context-integration region.

The results separated cleanly by region. Glutamate in the medial prefrontal cortex increased during psilocybin, and the magnitude of that increase correlated with the intensity of negative ego dissolution: the anxiety, confusion, or destabilizing quality of losing self-boundaries. Glutamate in the hippocampus decreased, and the magnitude of that decrease correlated with the intensity of positive ego dissolution: the oceanic feeling, the sense of unity, the positively experienced dissolution of self.

Two regions, two opposite directions, two different experiential correlates. The same drug producing both simultaneously — depending on where in the brain you measure.

This is not a theoretical model. It is a direct measurement of glutamate changes in human beings during the experience itself, with the subjective reports collected in the same session.

Why Serotonin Is Not the Whole Story: The Cascade That Follows Receptor Binding

The glutamate changes Mason measured are not coincidental. They follow directly from psilocybin's primary mechanism.

Szpregiel and colleagues reviewed the psilocybin-glutamate connection in 2024, synthesizing the mechanistic evidence across animal and human studies.^[2] The sequence works as follows.

Psilocin binds 5-HT2A receptors concentrated on the apical dendrites of cortical pyramidal cells. These are excitatory cells that form the output layer of the cortex. When the 5-HT2A receptor activates, it triggers intracellular G protein signaling that depolarizes the pyramid cell and drives it toward firing. When pyramidal cells fire, they release glutamate.

That glutamate then acts on two populations of cells. It activates excitatory glutamate receptors on downstream cortical neurons, amplifying network-wide excitation. It simultaneously activates glutamate receptors on GABAergic interneurons — inhibitory cells that provide local feedback. The interplay between the pyramidal cell excitation and the subsequent GABAergic inhibition creates the oscillatory changes in cortical activity that neuroimaging studies consistently detect during psilocybin sessions.

Kwan and colleagues confirmed in their 2022 Nature Neuroscience review that the intracellular cascade following 5-HT2A activation extends beyond G protein signaling to include calcium release and diacylglycerol (DAG) signaling, both of which contribute to structural plasticity changes in the hours and days following exposure.^[3] These plasticity changes — new synaptic connections forming, dendritic spine density increasing — are mediated by the calcium and DAG pathway, not by the serotonin receptor directly. The serotonin receptor starts the process. The glutamate and downstream signaling sustain it and extend it into lasting structural change.

The Region Story: Why mPFC and Hippocampus Go in Opposite Directions

The Mason 2020 finding raises an immediate question: why would glutamate increase in the prefrontal cortex while decreasing in the hippocampus in the same person at the same time?

The answer lies in the different 5-HT2A receptor density and local circuit architecture of the two regions. The medial prefrontal cortex is heavily loaded with 5-HT2A receptors on pyramidal cells and shows strong direct glutamate release upon psilocin binding. The hippocampus has a different receptor distribution and is influenced more by the circuit-level effects of frontal glutamate changes than by direct local 5-HT2A activation. When the frontal output increases, hippocampal glutamate may actually decrease as a downstream consequence of altered top-down signaling — the frontal cortex, usually modulating hippocampal input selection, starts behaving differently.

This regional specificity matters for understanding the experience. The prefrontal cortex is the brain's self-monitoring and narrative-generating region. Increased glutamate there, in the context of disrupted default mode network activity, may contribute to the anxious, disorienting quality that some people experience when self-referential thinking becomes hyperactivated before it dissolves. The hippocampus, involved in contextual memory and spatial processing, contributes differently to the experience — and its decreased glutamate may underlie the timeless, context-free quality that characterizes positive ego dissolution.

Szpregiel 2024 notes that both the prefrontal and hippocampal glutamate changes contribute to the neuroplasticity outcomes that follow psilocybin sessions.^[2] Increased frontal glutamate drives the formation of new cortical synapses; altered hippocampal activity influences memory consolidation and contextual learning. This may explain why the therapeutic benefits of a single psilocybin session persist for weeks to months after the drug has fully cleared.

For more on how these connectivity changes manifest across brain networks, see Beyond 5-HT2A: Other Serotonin Receptors Psilocybin Activates.

From Addiction to Neuroplasticity: What Glutamate Receptor Research Reveals

One of the most specific findings on psilocybin and glutamate comes from addiction research, not consciousness research.

Meinhardt and colleagues showed in 2021 that chronic alcohol consumption in an animal model causes significant downregulation of mGluR2 receptors in the prefrontal cortex.^[4] The mGluR2 receptor, a metabotropic glutamate receptor, acts as a presynaptic autoreceptor: it senses glutamate in the synapse and, when activated, reduces further glutamate release. Think of it as a volume knob that prevents glutamate from becoming excessive. Alcohol appears to turn this knob down by reducing how many of these receptors are present.

The consequence is a glutamate system in the prefrontal cortex that becomes dysregulated: less able to moderate its own excitatory output, contributing to the impulsive and craving-driven behavioral patterns of alcohol dependence.

Meinhardt found that psilocybin administration reversed this mGluR2 downregulation. It restored glutamate receptor density in the prefrontal cortex and reduced craving behavior in the animal model. This is not a serotonin effect. It is a direct engagement with the glutamate receptor system, normalizing a receptor whose dysfunction is central to addiction pathology.

The implication is that part of psilocybin's therapeutic benefit — not just in addiction but potentially in depression and other conditions where prefrontal glutamate regulation is impaired — may involve restoring the homeostatic machinery of glutamate signaling, not just transiently altering its levels.

For context on how the circuit models situate these effects, see REBUS Model: How Psilocybin Relaxes the Brain's Beliefs.

Dopamine: The Third Neurotransmitter System in the Picture

Glutamate is not the only additional neurotransmitter that psilocin engages beyond serotonin.

Sakashita and colleagues measured extracellular dopamine and serotonin levels in two rat brain circuits in 2015: the mesoaccumbens pathway, which connects the ventral tegmental area to the nucleus accumbens and governs reward and motivation, and the mesocortical pathway, which connects the same origin to the prefrontal cortex and governs executive function.^[6]

Psilocin administration significantly altered extracellular dopamine levels in both pathways, not just serotonin. The dopaminergic response was distinct from the serotonergic response in timing and magnitude, suggesting independent engagement of dopamine circuitry rather than a simple serotonin-mediated secondary effect.

The dopaminergic reward circuits are implicated in motivation, pleasure, and the emotional charge that makes experiences feel significant. Their involvement helps explain why the psilocybin experience so often involves an intensified sense of meaning or emotional weight attached to perceptions and memories — effects that serotonin receptor activation alone would not predict.

The multi-system picture from Kwan 2022's Nature Neuroscience review frames this clearly: psilocybin operates as a multi-channel brain modifier that engages serotonin, glutamate, dopamine, and intracellular plasticity signaling simultaneously, with the relative contribution of each varying by brain region, dose, and individual neurochemical baseline.^[3]

How Glutamate Fits the Circuit Models

The glutamate data does not exist in isolation. It connects to the three primary circuit-level models for psychedelic action that Doss and colleagues synthesized in 2022.^[5]

The first is the CSTC model: the cortico-striato-thalamo-cortical loop. In this model, psilocybin reduces striatal inhibition of the thalamus, opening thalamic gates and flooding the cortex with unfiltered sensory input. The glutamate cascade from cortical pyramidal cells amplifies this — increased frontal glutamate activity contributes to the cortical excitation that defines the experience.

The second is the REBUS model: relaxed beliefs under psychedelics, from Carhart-Harris and Friston. In this framework, the brain's top-down predictions become less rigid, and bottom-up sensory information is weighted more heavily. The glutamate release from pyramidal cells is the cellular mechanism that generates this increased bottom-up signal.

The third is the CCC model: cortico-claustro-cortical network. The claustrum, a thin structure behind the prefrontal cortex, acts as an orchestra conductor for cross-cortical communication. Psilocybin disrupts claustrum activity through serotonin receptors, but the glutamate cascade from disrupted frontal pyramidal cells contributes to the resulting network desynchronization. Anderson and colleagues showed in 2024 that multiple 5-HT receptor subtypes regulate claustrum excitability, extending the picture beyond 5-HT2A alone.^[7]

Glutamate is not a separate mechanism from these circuit models. It is the cellular-level translation of the serotonin receptor signal into the network-level changes that the models describe.

For more on the claustrum specifically, see The Claustrum and Psilocybin: A New Theory of Consciousness. For the thalamic gating mechanism, see Thalamic Gating and Psilocybin: How It Floods the Brain with Input. For the sigma-1 receptor angle, which remains more speculative for psilocybin specifically, see Psilocybin and Sigma-1 Receptors: Emerging Research.

The Bottom Line

Psilocybin's 5-HT2A activation triggers a glutamate cascade in cortical pyramidal cells, producing region-specific changes in the prefrontal cortex and hippocampus that predict both the subjective quality of ego dissolution and the neuroplastic outcomes that follow. Mason et al. 2020 demonstrated this with direct 7T MRI glutamate measurement during live psilocybin sessions. Meinhardt et al. 2021 showed psilocybin engages mGluR2 receptor density directly, normalizing glutamate homeostasis in addiction models. Sakashita 2015 established dopaminergic involvement alongside glutamatergic effects, making psilocybin a multi-neurotransmitter modifier. Kwan 2022 and Doss 2022 provide the integrative frameworks placing glutamate within the broader circuit models.

Frequently Asked Questions

Does psilocybin affect glutamate?

Yes. Psilocybin's 5-HT2A receptor activation on cortical pyramidal cells triggers glutamate release as a direct downstream effect. Mason et al. 2020 measured this directly with 7T MRI in humans, finding region-specific glutamate changes that correlated with ego dissolution quality. Szpregiel et al. 2024 reviewed the full cascade: 5-HT2A → pyramidal cell excitation → glutamate release → GABAergic interneuron activation → network-level oscillation changes.

What neurotransmitters does psilocybin affect besides serotonin?

Glutamate is the primary secondary neurotransmitter — released by cortical pyramidal cells following 5-HT2A activation. Dopamine is also affected: Sakashita et al. 2015 found psilocin altered extracellular dopamine in both the mesolimbic (reward) and mesocortical (executive function) pathways in rats. Kwan et al. 2022's Nature Neuroscience review confirmed the multi-system picture, including GABA interneuron involvement as part of the glutamate cascade.

How does psilocybin change glutamate in the brain?

Differently by region. In the medial prefrontal cortex, psilocybin increases glutamate — and the magnitude of this increase correlates with negative ego dissolution (Mason 2020). In the hippocampus, glutamate decreases — and the magnitude of that decrease correlates with positive ego dissolution. The opposite directional changes in the same person reflect the different local circuit architecture and receptor distributions in each region.

What is the non-serotonin mechanism of psilocybin?

The primary non-serotonin mechanism is the glutamate cascade: 5-HT2A receptor activation on pyramidal cells drives glutamate release, which then activates excitatory glutamate receptors on downstream neurons and inhibitory glutamate receptors on GABAergic interneurons. Beyond this, psilocybin also engages dopaminergic circuits (Sakashita 2015), mGluR2 glutamate receptor homeostasis (Meinhardt 2021), and intracellular calcium and DAG signaling pathways that underlie structural plasticity (Kwan 2022).

Does psilocybin cause ego dissolution through glutamate?

Glutamate mediates significant aspects of ego dissolution, but not all of it. Mason et al. 2020 is the clearest evidence: glutamate changes in the medial prefrontal cortex and hippocampus directly predicted the character of ego dissolution in a controlled human study. The direction and location of glutamate change influenced whether dissolution felt positive (oceanic, unifying) or negative (anxious, destabilizing). The serotonin receptor triggers the initial cellular response; the resulting glutamate changes shape much of what follows.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.